# Study to Assess Efficacy and Safety of Zoledronic Acid and the Value of Markers of Bone Resorption in the Prediction of Bone Metastases and Cancer Treatment-induced Bone Loss (CTIBL) in Patients With Prostate Cancer on Hormone Therapy

> **NCT00172055** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 218 (actual)

## Conditions studied

- Cancer Prostate

## Interventions

- **DRUG:** Zoledronic acid

## Key facts

- **NCT ID:** NCT00172055
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** 2009-07
- **Final completion:** 2009-07
- **Target enrollment:** 218 (ACTUAL)
- **Last updated:** 2017-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00172055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00172055, "Study to Assess Efficacy and Safety of Zoledronic Acid and the Value of Markers of Bone Resorption in the Prediction of Bone Metastases and Cancer Treatment-induced Bone Loss (CTIBL) in Patients With Prostate Cancer on Hormone Therapy". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00172055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*